120 related articles for article (PubMed ID: 22166793)
1. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss.
Aarts E; Helmich RC; Janssen MJ; Oyen WJ; Bloem BR; Cools R
Neuroimage; 2012 Feb; 59(4):3339-46. PubMed ID: 22166793
[TBL] [Abstract][Full Text] [Related]
2. On the role of dopamine replacement therapy in decision-making, working memory, and reward in Parkinson's disease: does the therapy-dose matter?
Torta DM; Castelli L; Zibetti M; Lopiano L; Geminiani G
Brain Cogn; 2009 Nov; 71(2):84-91. PubMed ID: 19442427
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
[TBL] [Abstract][Full Text] [Related]
4. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
5. Effects of asymmetric dopamine depletion on sensitivity to rewarding and aversive stimuli in Parkinson's disease.
Maril S; Hassin-Baer S; Cohen OS; Tomer R
Neuropsychologia; 2013 Apr; 51(5):818-24. PubMed ID: 23422331
[TBL] [Abstract][Full Text] [Related]
6. Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology.
Robert G; Drapier D; Verin M; Millet B; Azulay JP; Blin O
Mov Disord; 2009 Dec; 24(16):2316-27. PubMed ID: 19908312
[TBL] [Abstract][Full Text] [Related]
7. Greater striatal responses to medication in Parkinson׳s disease are associated with better task-switching but worse reward performance.
Aarts E; Nusselein AA; Smittenaar P; Helmich RC; Bloem BR; Cools R
Neuropsychologia; 2014 Sep; 62():390-7. PubMed ID: 24912070
[TBL] [Abstract][Full Text] [Related]
8. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
Tomer R; Aharon-Peretz J; Tsitrinbaum Z
Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
[TBL] [Abstract][Full Text] [Related]
9. Selective impairment of prediction error signaling in human dorsolateral but not ventral striatum in Parkinson's disease patients: evidence from a model-based fMRI study.
Schonberg T; O'Doherty JP; Joel D; Inzelberg R; Segev Y; Daw ND
Neuroimage; 2010 Jan; 49(1):772-81. PubMed ID: 19682583
[TBL] [Abstract][Full Text] [Related]
10. Fronto-striatal atrophy correlates of inhibitory dysfunction in Parkinson's disease versus behavioural variant frontotemporal dementia.
O'Callaghan C; Naismith SL; Hodges JR; Lewis SJ; Hornberger M
Cortex; 2013; 49(7):1833-43. PubMed ID: 23306064
[TBL] [Abstract][Full Text] [Related]
11. Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease.
Péron J; Vicente S; Leray E; Drapier S; Drapier D; Cohen R; Biseul I; Rouaud T; Le Jeune F; Sauleau P; Vérin M
Neuropsychologia; 2009 Jan; 47(2):406-14. PubMed ID: 18845171
[TBL] [Abstract][Full Text] [Related]
12. How attentional boost interacts with reward: the effect of dopaminergic medications in Parkinson's disease.
Kéri S; Nagy H; Levy-Gigi E; Kelemen O
Eur J Neurosci; 2013 Dec; 38(11):3650-8. PubMed ID: 24011183
[TBL] [Abstract][Full Text] [Related]
13. Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing.
Mongeon D; Blanchet P; Messier J
Neuroscience; 2009 Jan; 158(2):426-40. PubMed ID: 18996173
[TBL] [Abstract][Full Text] [Related]
14. Action naming in Parkinson's disease patients on/off dopamine.
Herrera E; Cuetos F
Neurosci Lett; 2012 Apr; 513(2):219-22. PubMed ID: 22387157
[TBL] [Abstract][Full Text] [Related]
15. Delay discounting of reward and caudate nucleus volume in individuals with α-synuclein gene duplication before and after the development of Parkinson's disease.
Szamosi A; Nagy H; Kéri S
Neurodegener Dis; 2013; 11(2):72-8. PubMed ID: 23038403
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric dopamine loss differentially affects effort to maximize gain or minimize loss.
Porat O; Hassin-Baer S; Cohen OS; Markus A; Tomer R
Cortex; 2014 Feb; 51():82-91. PubMed ID: 24267688
[TBL] [Abstract][Full Text] [Related]
17. Impact of Parkinson's disease and dopaminergic medication on adaptation to explicit and implicit visuomotor perturbations.
Mongeon D; Blanchet P; Messier J
Brain Cogn; 2013 Mar; 81(2):271-82. PubMed ID: 23313834
[TBL] [Abstract][Full Text] [Related]
18. Impulsive and compulsive behaviors in Parkinson's disease.
Evans AH; Strafella AP; Weintraub D; Stacy M
Mov Disord; 2009 Aug; 24(11):1561-70. PubMed ID: 19526584
[TBL] [Abstract][Full Text] [Related]
19. [Placebo effect in Parkinson's disease].
Miwa H
No To Shinkei; 2007 Feb; 59(2):139-46. PubMed ID: 17315755
[TBL] [Abstract][Full Text] [Related]
20. Predictors of impulsivity and reward seeking behavior with dopamine agonists.
Ondo WG; Lai D
Parkinsonism Relat Disord; 2008; 14(1):28-32. PubMed ID: 17702628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
